GvHD Treatment Methods Using IL-22 Dimer
Summary
USPTO published patent application US20260108616A1 covering methods for treating graft versus host disease (GvHD) by administering a composition comprising an IL-22 dimer, optionally combined with immunosuppressive therapy, across multiple treatment cycles separated by rest periods. Inventors William DALEY and Xiaoqiang YAN filed the application on December 19, 2025; the application was published on April 23, 2026.
“The present application provides methods for treating graft versus host disease (GvHD) by administering a composition an agent comprising an IL-22 (such as an IL-22 dimer), and optionally an immunosuppressive therapy.”
About this source
GovPing monitors USPTO Patent Applications - Therapeutics (A61P) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 219 changes logged to date.
What changed
USPTO published patent application US20260108616A1 titled 'Methods for Treating Graft Versus Host Disease,' filed by William DALEY and Xiaoqiang YAN. The application claims methods of treating GvHD by administering a composition comprising an IL-22 dimer, with optional combination with immunosuppressive therapy, suitable for multiple treatment cycles separated by rest periods, and including patient-selection criteria based on Ann Arbor score or gut microbiota profile. The filing date is December 19, 2025, and the publication date is April 23, 2026.
Pharmaceutical companies engaged in biologics development, immunotherapy research, or transplant-related therapeutic programs should review this filing to assess Freedom to Operate considerations, potential licensing opportunities, or overlapping patent territory in the IL-22 dimer and GvHD treatment space.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
METHODS FOR TREATING GRAFT VERSUS HOST DISEASE
Application US20260108616A1 Kind: A1 Apr 23, 2026
Inventors
William DALEY, Xiaoqiang YAN
Abstract
The present application provides methods for treating graft versus host disease (GvHD) by administering a composition an agent comprising an IL-22 (such as an IL-22 dimer), and optionally an immunosuppressive therapy. The treatment can be administered for multiple cycles which are separated by a rest period and/or individuals who have a specific Ann Arbor score or a characterized gut microbiota profile. The present application also provides methods of identifying or selecting individuals suitable for such treatments.
CPC Classifications
A61K 47/642 A61K 31/573 A61P 37/06
Filing Date
2025-12-19
Application No.
19426688
Mentioned entities
Parties
Related changes
Get daily alerts for USPTO Patent Applications - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.